PATENT CLAIM ANALYSIS

Application Number: 16207637
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "085200"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 92):
The method of  claim 78 , wherein the carrier consists of the amino acid sequence set forth in SEQ ID NO: 3, conjugated to the human growth hormone consisting of the amino acid sequence set forth in SEQ ID NO: 95.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16207611', '15309177', '15616140', '14627992', '12950500']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7660480845933457
- 35 USC 102 Novelty (BERT): 0.5797448719792784
- Combined Prediction Score: 0.747417763331939
- Mean Citation Score: 386.753932
- Max Citation Score: 528.9387
- Similarity Product: 379.1794713977516

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test